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Abstract
In 30–50% of patients with metastatic non-medullary thyroid cancer the metastases are not
radioiodine-avid and so there is no effective treatment. Retinoids have demonstrated inhibition of
thyroid tumor growth and induction of radioiodine uptake. The aim of our study was to assess
benefits of the retinoic acid (RA) treatment to re-differentiate non-functional NMTC metastases.
Patients and Methods: In this prospective study, 53 patients with radioiodine non avid
metastatic disease (45) or hyperthyroglobulinemia (8) were treated with 13-cis-retinoic acid (13-
CRA) [1.0 mg/kg/day over 1st week and then 1.5 mg/kg] for six weeks prior to I-131 treatment
performed under rhTSH stimulation. The re-differentiating effect of RA was evaluated by serum
thyroglobulin (Tg) monitoring before and after cessation of RA treatment and by qualitative analysis
of iodine uptake on the post-therapeutic whole body scan (rxWBS).
Results: 13-CRA induced radioiodine uptake in 9 (17%) of patients. In the univariate analysis
neither the patient's gender, age, tumor histopathology, uptake in thyroid bed nor time since
thyroid cancer diagnosis was associated with results of rxWBS.
41 (77%) patients were evaluable for Tg response before and after to 13-CRA treatment. There
was a statistically significant increase in median Tg level (60 v. 90 ng/ml, p < 0.05). There was no
difference in Tg increase between scintigraphic responders and non-responders.
13-CRA and RIT was repeated at least once in 8 of 9 scintigraphic responders. None of them
showed tumor regression by radiological imaging within 12 months after the first treatment, 4/9
(44%) of them had disease progression.
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13-CRA treatment was well-tolerated. All but one patient complained of at least one side effect
the most prevalent being lip dryness (98%). All side effects were transient and resolved within 2
weeks after 13-CRA cessation.
Conclusion: Our results show that in patients with non-functional metastases from NMTC, 13-
CRA is able to exert some re-differentiation effect by induction of radioiodine uptake in <20% of
patients and increase of Tg serum level in about 30% of them. Nevertheless, this does not transfer
into clinical benefit as it neither induces measurable tumor response nor prevents disease
progression.
Introduction
Soon after the introduction of 131-iodine (131-I) for
treatment of thyroid cancer deriving from follicular cells
(non-medullary thyroid carcinoma, NMTC) [1] it became
evident that at least 30% of these tumors fail to concen-
trate radioiodine even after thyroid hormone withdrawal
(THW) [2]. Over the ensuing decades, radioiodine non-
avid thyroid cancer has remained a therapeutic challenge.
Patients with non-functional thyroid cancer foci continue
to have a much worse prognosis than their counterparts
with 131-I uptake [3,4], and lack therapeutic options.
Metastasectomy is useful solely in occasional patients
with solitary, mainly bone lesions [5], while external radi-
ation therapy can only palliate metastatic symptoms [6].
Conventional chemotherapy, i.e., doxorubicin alone or
with cisplatin, is very toxic and provides merely a <20%
rate of mostly very transient, partial responses [7].
In recent years, research has focused on targeted
approaches addressing the pathological characteristics of
radioiodine non-avid thyroid carcinoma. It has been
known that inability to take up 131-I is associated with
poor differentiation and increased tumor grade [3]. How-
ever, the molecular basis of loss of function is not well
known. Thus far, p53 mutation is the only genetic change
clearly shown to correlate with poor differentiation or
lacking differentiation. Other molecular events known to
occur in NMTC like decrease or loss of sodium-iodine
symporter (NIS) expression or of other thyroid-specific
molecules (5'-DI [type I iodothyronine-5'-deiodinase],
TSH receptor, pendrin) are rather consequences of earlier
molecular processes. Some recent reports show a signifi-
cant correlation between the presence of initiating BRAF
mutation and poorer outcome of DTC (differentiated thy-
roid cancer) or loss of function of DTC metastases [8].
However, BRAF mutation is a rather frequent initiating
event in DTC (40–60% of all cases), while poor differen-
tiation and progressive course are observed only in a sig-
nificantly smaller fraction (circa 10–15%) of them. Thus,
molecular processes linking BRAF mutation with still
unknown events leading to increased proliferation and
decreased function in this subset need to be uncovered.
Retinoids are a family of substances including the biolog-
ically active vitamin A metabolites, the retinoic acids
(RA), that play an important role in morphogenesis, dif-
ferentiation and proliferation of many cell types [9,10]. In
NMTC tumor cells, experimental data demonstrate that
retinoids can inhibit tumor growth and induce radioiod-
ine uptake [11]. Additionally, retinoids exert several re-
differentiating effects: induction of 5'-DI [12,13]
increased expression of NIS mRNA [14] and of the differ-
entiation marker, alkaline phosphatase, or decreased
expression of CD97, which is highly expressed in anaplas-
tic thyroid carcinoma [15], as well as stimulation of inter-
cellular adhesion molecule-1 synthesis [16]. Although
leading to partial rather than complete thyroid cancer cell
re-differentiation, these effects have been hoped to render
radioiodine uptake and enable treatment of NMTC foci
[17-22]. The promising experimental results and their
potential therapeutic impact prompted a number of cent-
ers including ours to initiate clinical studies to evaluate
the effectiveness of 13-cis-retinoic acid (13-CRA) as re-dif-
ferentiation therapy (RDT) in patients with advanced
radioiodine non-avid thyroid cancer. In contrast to other
investigators, we performed the radioiodine therapy
under recombinant human TSH (rhTSH) stimulation
rather than under thyroid hormone withdrawal (THW).
Our rationale for doing so was twofold. Firstly, we wished
to avoid possible additive or synergistic toxicity of high-
dose RA and of hypothyroidism secondary to THW, which
have potentially overlapping symptoms, namely, depres-
sion, headache, increased lipidaemia, dry skin or/and
mucosa, and musculo-articular pain [19]. Secondly, we
sought to compare concentrations of serum thyroglobulin
(Tg) as the marker of thyroid cancer differentiation, before
and after RA therapy without the confounding factor of
weeks-long TSH elevation.
Method
Study Design and Ethical Considerations
This was a prospective phase II observational study. The
protocol (Figure 1) was approved by the local ethics com-
mittee. All patients were informed of the nature, aim and
potential risks of the study therapy and provided written
consent before the treatment was initiated.Thyroid Research 2009, 2:8 http://www.thyroidresearchjournal.com/content/2/1/8
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The primary endpoint was the: (1) the qualitative effect of
13-CRA RDT on 131-I uptake in confirmed non-func-
tional NMTC metastases (scintigraphic response) and (2)
the quantitative effect of 13-CRA RD Ton thyroglobulin
serum level during therapy course. Secondary endpoints
comprised tolerance of 13-CRA RDT/rhTSH-aided radio-
iodine treatment (rhTSH RIT) and tumor response in scin-
tigraphic responders.
Inclusion criteria were: (a) metastatic or locoregionally
advanced, papillary, follicular or poorly differentiated
thyroid cancer, both with stable or progressive course of
the disease; (b) no radioiodine uptake in known meta-
static thyroid cancer foci on the most recent post-therapy
whole body scintigraphy (rxWBS) and (c) no prior retin-
oid RDT. Exclusion criteria included: (a) anaplastic thy-
roid cancer; (b) pregnancy or lactation; (c) life expectancy
> 6 months; (d) serum transaminase (AST, ALT) < 80
mUI/ml; (e) serum total cholesterol < 360 mg/ml; and (f)
serum triglycerides < 250 mg/%, (g) administration of
iodine-containing drugs less than 3 months before
planned radioiodine therapy.
Study Population
The study population included all eligible patients (n =
53) who agreed to receive 13-CRA RDT and rhTSH RIT at
our tertiary referral centre from 1999 – 2004. The group
tended to be of mid-late middle age at study entry and was
nearly 2/3 female; a similar proportion of patients had
papillary histology at diagnosis (Table 1). All but one
patient had been treated at least once with 131-I (up to
five therapies) with a median accumulated activity of 6.66
GBq. In all but one case the therapies were performed
under endogenous TSH stimulation (TSH > 25 mIU/ml).
One patient was included who had not previously
received radioiodine and hence had no prior rxWBS. This
patient had been diagnosed with poorly-differentiated
follicular cancer diffusely metastasized to bone and non-
functional disease was confirmed by diagnostic WBC
(dxWBS).
Forty-five (85%) of the 53 patients suffered from overt
disease, which in all instances was radiologically or ultra-
sonographically confirmed, or both. All cases of locore-
gional disease were confirmed by fine needle biopsy as
well. As seen in Table 1, the most prevalent metastatic
involvement was of the lung and of the neck lymph
nodes, thyroid bed or both ("locoregional" sites). Metas-
tases to multiple sites were detected in 10 (19%) patients.
Median time from the disease diagnosis to diagnosis of
metastatic disease was 30 months (range 0 – 171). In 13
patients metastases were diagnosed within a year after the
diagnosis of thyroid cancer and in 5 of them more than 10
years after the primary diagnosis. Eight (15%) patients
were diagnosed with hyperthyroglobulinaemia in range
of 11–100 ng/ml during L4-therapy, which was presumed
to reflect occult nonfunctional micrometastases (no radi-
oiodine uptake nor abnormalities in radiological exami-
nations).
Study design Figure 1
Study design. Radioiodine non-avid disease was confirmed by a negative post-therapy whole-body scan plus radiological imag-
ing. Study day scale is not drawn proportionally. RAI, radioiodine treatment; rxWBS, post-therapy whole-body scan (* TSH, Tg, 
rTg, morphology, transaminase, cholesterol, creatinine. ** morphology, transaminase, cholesterol, creatinine, in 20 patients 
also TSH, Tg, rTg. *** TSH, Tg, rTg)Thyroid Research 2009, 2:8 http://www.thyroidresearchjournal.com/content/2/1/8
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Forty nine (92%) patients were previously treated with at
least one RIT in our centre. Three (6%) were referred to us
after being treated elsewhere and had their post-therapy
scans sent to us for evaluation. As already mentioned, the
negative post-radioiodine therapy scan was available in all
but one patient. In 21 (42%) patients negative rxWBS was
followed-up by negative diagnostic WBS. In no instance
the most recent WBS did show any radioiodine uptake in
any metastasis, but some physiological thyroid bed
uptake was visible on rxWBS in 10 (19%) patients (Table
2) who were treated after total thyroidectomy. From 36
patients who were treated more than two times before 13-
CRA RDT, in 32 there was no other uptake than in thyroid
bed, and in 4 patients initially there was some very weak
uptake in metastatic sites that was no more visible in sub-
sequent treatments.
For 23 patients in the present series, earlier results have
been reported elsewhere [31]
13-CRA RDT
RDT with 13-CRA (Roaccutan®, Roche AG, Germany) was
started 6 weeks before radioiodine administration (Figure
1). The dosage was 1.0 mg/kg of body weight/day during
Table 1: Characteristics of 53 patients receiving 13-cis-retinoic acid at start of re-differentiation therapy
Characteristic Value
Female, n (%) 34 (64%)
Age at thyroid cancer diagnosis (years), median (range) 57 (15 – 69)
Primary histopathology, n (%)
papillary 34 (64%)
follicular 17 (32%)
insular 2 (4%)
Localization of metastatic disease, n (%)*:
lung 31 (58%)
locoregional disease 13 (25%)
hyperthyroglobulinaemia 8 (15%)
bones 6 (11%)
other 5 (9%)
Previous radioiodine treatments
number, median (range) 2 (0–5)
cumulative activity – GBq; median (range) 6.66 (0.00–15.54])
Time from thyroid cancer diagnosis to 13-CRA RDT, median (range) 54 (6–186) months
* the sum is bigger than 53 as in some patients there were more than one disease localization
Table 2: Scintigraphic findings after 13-CRA therapy in 53 patients with radioiodine non-avid NMTC metastases
WBS after redifferentiation therapy Last pre redifferentiation WBS
No uptake Uptake in thyroid bed
No scintigraphic response in metastases 35* (66%) 8 (15%)
Scintigraphic response in metastases 8 (15%) 1 (2%)
Lung 5( 9 % )0 ( 0 % )
Mediastinum 1 (2%) 1 (2%)
Lung and lymph node 1 (2%) 0 (0%)
Lung and bone 1 (2%) 0 (0%)
Persistent thyroid bed uptake in pre- and post-13-CRA RDT rxWBS 0 (0%) 1 (2%)
13-CRA, 13-cis-retinoic acid; RDT, re-differentiation therapy;
rxWBS, post-therapy whole-body scintigraphy
* in one patient there was only diagnostic WBC for comparisonThyroid Research 2009, 2:8 http://www.thyroidresearchjournal.com/content/2/1/8
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the first week and if that dose was tolerated, 1.5 mg/kg/
day for the next 5 weeks, during which time dose reduc-
tion to 1.0 mg/kg was allowed in case of drug intolerance.
RIT
RIT was performed under exogenous stimulation with two
consecutive daily intramuscular injections of 0.9 mg of
rhTSH (Thyrogen®, Genzyme Corporation, Cambridge,
MA) on study days 42 and 43. On study day 44, a fixed
empirical therapeutic radioiodine activity of 3.70 GBq, (in
2 patient 5.55 GBq was applied) was given by oral cap-
sule. When the first study rxWBS showed radioiodine
uptake in one or more metastatic sites, the study treat-
ments were repeated at 6-month intervals, until patholog-
ical uptake was lost on rxWBS due to cure or disease
progression. When the initial study rxWBS was negative,
the patient resumed follow-up and medical care in his/her
community.
Endpoint Assessment
The effect of 13-CRA RDT on 131-I uptake was evaluated
through qualitative assessment of the study day 47 rxWBS
for such uptake in sites of previously confirmed radioiod-
ine non-avid metastases (based on "yes/no"answer).
Three experienced nuclear medicine physicians (DHJ, JR,
BJ) rated these sites for scintigraphic response, i.e., pres-
ence or absence of visual uptake. In case of discrepant rat-
ings the scans were reevaluated by three physicians
together. The patient was evaluated as scintigraphic
responder when at least one focus of definite 131-I uptake
was diagnosed concordantly with localization of known
metastasis.
rxWBS was performed 3 days after the second rhTSH injec-
tion using a dual-head gamma camera (Siemens Multi-
spect 2) with parallel high-energy collimators, for at least
140,000 counts or 20 minutes of acquisition. Single spot
images of regions containing known or suspected metas-
tases were taken for at least 80,000 counts.
Tg levels were compared in blood samples obtained
within 7 days before the start of 13-CRA RDT, versus in
those obtained on study day 42. Study day 42 sampling
took place before the first rhTSH injection, which also was
given that day. To place into context any effect of 13-CRA
RDT on serum Tg concentrations, Tg levels in the study
day 42 sample also were compared with those in the sam-
ple taken on study day 47, 3 days after the second and last
rhTSH injection. To establish physiological variations in
serum Tg concentration, this analyte was additionally
measured one day before last 13-CRA application in 20
(38%) randomly chosen patients. The highest difference
between these two measurements was 30%. Thus an
increase of ≥30% over pre-RDT levels was chosen to
denote a clinically relevant change in Tg and the patient
was evaluated as biochemical responder when the rise in
serum Tg exceeded 30%.
Tg was measured by immunofluorometric assay (Wallac
Delfia) with functional sensivity of 1 ng/ml. Interference
by anti-Tg antibodies was ruled out via Tg recovery testing
performed simultaneously with the Tg assay. Recovery
beneath our institutional cut-off of 70% was considered
to denote such interference, and caused the patient to be
excluded from further Tg analysis [23].
Side effects of 13-CRA RDT were assessed through struc-
tured questioning of patients and by caregiver observation
after 3 weeks and at the end of therapy. Known potential
symptoms of 13-CRA including depression, headache,
vision problems, hearing loss, nosebleed, skin, dry, itch-
ing or peeling lips, skin, or other mucosa, and musculo-
articular pain were specifically sought. Lipaemic effects
and hepatotoxicity were assessed through measurement
of serum cholesterol, triglyceride and transaminase levels
in blood samples taken on days 1, 21 and 42. Addition-
ally, patients were requested to spontaneously report any
apparent side effects or health status changes throughout
the study.
Tumor response to the study treatment was evaluated only
in scintigraphic responders, by physical, scintigraphic and
radiological (contrast enhanced computer tomography)
examinations performed immediately after the first course
of 13-CRA RDT/rhTSH RIT and after subsequent courses.
Statistical Methods
A p value ≤ 0.05 was deemed significant. The chi-square
test was used to compare frequencies in subgroups. Thy-
roglobulin measurements (non normal distribution)
were compared with the Wilcoxon nonparametric
matched pairs test. The univariate analysis was conducted
to identify independent predictive factors for scintigraphic
response. Statistical analyses were performed with the Sta-
tistical for Windows package (Statsoft Polska, Kraków,
Poland).
Results
Scintigraphic Response
Forty-four (83%) of 53 patients had no uptake and 9
(17%) showed uptake in known metastatic sites (Table 2).
In one of the scintigraphic responders the latest THW-
aided rxWBS showed uptake in thyroid bed. One of ten
patients with thyroid bed uptake on the latest THW-aided
rxWBS retained such uptake on the study day 47 rxWBS
(Table 2).
Potential Predictive Factors for Scintigraphic Response
In univariate analysis, neither the patient's gender, age,
tumor histopathology at diagnosis, 131I uptake in thyroidThyroid Research 2009, 2:8 http://www.thyroidresearchjournal.com/content/2/1/8
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bed during the last pre study RIT or time since thyroid can-
cer diagnosis was statistically significantly associated with
scintigraphic response (Table 3). Therefore no multivari-
ate analysis of potential predictive factors for scintigraphic
response was performed.
Thyroglobulin response
Six (11%) of 53 patients were considered to have interfer-
ence from anti-Tg antibodies based on Tg recovery <70%,
and were excluded from the analysis of Tg response. In
another 6 patients (11%), no evaluable pre-RDT blood
sample was available due to 13-CRA RDT being started by
the patient's local endocrinologist (n = 2) or due to the
patient erroneously withdrawing thyroid hormone before
13-CRA (n = 4, in all of whom thyroid hormone was re-
started on day 1 of 13-CRA RDT). Thyroglobulin levels at
the first and last 13-CRA RDT application are depicted in
additional file 1: thyroglobulin before and after 13-CRA
RDT.
Thus, 41 (77%) patients were evaluable for Tg response to
13-CRA RDT. In this group, baseline serum Tg levels at the
start of 13-CRA RDT ranged from 0.2 to 4079.0 ng/ml
(median 60.0 ng/ml, mean ± SD, 637 ± 1227 ng/ml). The
change between baseline and post-13-CRA RDT (i.e., day
42) Tg values was beneath the prospectively defined
>30% threshold for clinical relevance in 28 (68%) of the
41 and was above that threshold in 13 (32%) (see addi-
tional file 1: thyroglobulin before and after 13-CRA RDT).
In fact all of them exhibited the response of >50% of the
initial level. Thyroglobulin level increased in 1 (17%) out
of 6 evaluable patients with 13-CRA RDT-induced 131-I
uptake and in 12 (34%) out of 35 without radioiodine
uptake on rxWBS (p > 0.05).
The difference (n = 41) between the median pre- and post-
13-CRA RDT Tg concentration was statistically significant.
There was also a statistically significant difference between
the mean Tg values before and after rhTSH stimulation
(i.e., day 42 versus day 47 levels) (Figure 2).
In 7 patients (13% of evaluable patients, 54% of Tg
responders), the increase in Tg level after 6 weeks of 13-
CRA exceeded 75%. In Tg responders, the median base-
line serum Tg levels (36 ng/ml) at the start of 13-CRA RDT
was lower then in non-responders (94 ng 7 ml), but the
difference was statistically insignificant.
Side effects of 13-CRA and rhTSH aided radioiodine 
therapy
The first course of 13-CRA was well-tolerated. All patients
completed the therapy, and only 5 (9%) had toxicity that
necessitated reduction of the 13-CRA from 1.5 mg/kg/day
to the starting dose of 1 mg/kg/day
All but one patient complained of at least one side effect,
the most prevalent being lip dryness (52 patients, 98%).
The other most frequent side effects included skin dryness
Table 3: Univariate analysis of potential predictive factors for scintigraphic response to 13-cis-retinoic acid therapy
Variable Uptake in metastases (n = 9) No uptake in metastases (n = 44) P¶
Potential predictive factor
Sex Ns
Female (n = 34) vs. 7 (78%) 27 (61%)
Male (n = 19) 2 (22%) 17 (39%)
Histology Ns
Papillary (n = 34) vs. 4 (44%) 30 (68%)
Follicular (n = 17) vs. 4 (44%) 13 (30%)
Insular (n = 2) 1 (2%) 1 (2%)
Median age 54 59 Ns
Mean time since diagnosis of metastatic disease, years 5.3 3.5 Ns
Mean time since last 131-I therapy, months 19.4 15.3 Ns
Results of the last pre-redifferentiation post therapy WBS: Ns
uptake in thyroid bed 1 9
no uptake 8 35
¶ NS, not significant (P > 0.05)Thyroid Research 2009, 2:8 http://www.thyroidresearchjournal.com/content/2/1/8
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(31 patients, 58%) most intense on face and hands, skin
redness or mucosal dryness (21 patients, 39% each) or
musculo-articular pain (15 patients, 28%). All side effects
were transient and appeared to resolve within 2 weeks
after 13-CRA cessation.
In biochemical evaluation following the first course of 13-
CRA, a statistically significant increase from baseline to
day 42 concentrations was noted in mean serum triglycer-
ide, cholesterol and aspartate and alanine aminotrans-
ferase level (Table 4). Still, in none of the patients during
follow-up clinically relevant sequel, such as stroke, hart
attack or vain thrombosis, developed.
rhTSH injections were well tolerated. However, of note,
there was a case of a patient with a rapid progression of
bone metastases diagnosed within days after rhTSH. The
same effect was observed in this patient during the previ-
ous THW-based 131I therapy.
Subsequent Study Treatments and Outcome in 
Scintigraphic Responders
The study treatments were repeated at least once (median
3 times, range 1 to 5 times) in 8 of 9 scintigraphic
responders. One patient was lost from follow-up immedi-
ately after the first 131-I therapy. All subsequent courses
of 13-CRA RDT/rhTSH RIT resulted in qualitatively simi-
lar radioiodine uptake in metastases on rxWBS as it was
seen on the study day 47 rxWBS.
However, none of the 8 scintigraphic responders who
received repeated therapy, showed metastatic tumor
regression by radiological imaging. In fact, within 12
months after the first 13-CRA RDT/rhTSH RIT, 4/9 (44%)
of the patients had disease progression.
Discussion
The present single-center phase 2 trial of 6 weeks of 13-
CRA RDT followed by rhTSH RIT in 53 patients with con-
firmed radioiodine non-avid advanced NMTC resulted in
two main findings. Firstly, the study 13-CRA RDT regimen
appeared to exert true re-differentiating effects, but only in
Serum thyroglobulin changes during 13-cis-retinoic acid therapy and after administration of recombinant human thyroid-stimu- lating hormone therapy, 0.9 mg/day × 2 Figure 2
Serum thyroglobulin changes during 13-cis-retinoic acid therapy and after administration of recombinant 
human thyroid-stimulating hormone therapy, 0.9 mg/day × 2. Only patients (n = 41) showing no interference from 
anti-thyroglobulin antibodies, based on thyroglobulin recovery >70% were included. Hollow squares indicate the median value, 
while t bars indicate the 25% and 75% percentile. X-axis time scale is not exact.Thyroid Research 2009, 2:8 http://www.thyroidresearchjournal.com/content/2/1/8
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a minority of patients. These effects were manifested in
two ways: (1) the regimen induced 131-I uptake in previ-
ously non-functional metastases on rhTSH-aided rxWBS
in 9 (17%) of 53 of patients, and (2) a significant serum
Tg increase was observed in 13 of 41, or 32% of evaluable
patients. Observations from other clinical trials [20-22]
are not comparable with our study, and are, indeed, diffi-
cult to interpret, because of these trials' use of THW and
their lengthier interval between measurements, which
were conducted between RITs, i.e, months apart. To our
knowledge only one study [21] showed increase in Tg
concentration during and L-thyroxine therapy. However,
patients population was rather small. The change in Tg
serum level was measured after 1 month of therapy with
13-CRA, as at that point patients withdrew L-thyroxine
therapy. Higher than 30% increase in Tg serum level was
observed in 6/10 (60%) of evaluable patients in that study
(extracted from the raw data in manuscript). In our study
such increase was observed in 32% of patients and for our
evaluable patient population as a whole (n = 41), the
increase in mean Tg value over the course of 13-CRA RDT
was statistically significant. Because of our avoidance of
weeks-long THW and the resultant confounding factor of
TSH elevation and because of the short, 6-week interval
between measurements, Tg increases over the course of
RDT seen in our study are likely to represent true re-differ-
entiation effects rather than tumor growth. Laboratory
explanation for this observation is somehow controver-
sial. There are some experimental evidence for the phe-
nomenon of a RA-induced increase in Tg mRNA.
Kurebayashi et al. [24] showed an increase of Tg mRNA in
human poorly differentiated papillary thyroid carcinoma
cell line (KTC-1) after incubation with 1 μmol/l all-trans-
retinoic acid for 24 hours; however, others performing
similar experiments have reported unchanged Tg mRNA
expression [25].
With respect to incidence of scintigraphic response our
findings are less favorable than those of several previously
published studies. Grunwald et al. [18] reported markedly
increased uptake after 13-CRA RDT in 2 (17%) of 12
treated patients and in another 3 only a faint uptake. In
another trial qualitatively assessed radioiodine uptake
was increased in 9 (45%) of 20 patients [19]. However, in
the later study only 4 patients had completely negative
scan before 13-CRA RDT. In our study we observed induc-
tion of radioiodine uptake in 17% of treated patients.
Our trial's second main finding, and its observation of
greatest clinical relevance, is that the study regimen's re-
differentiation effects appear to be accompanied by little
if any clinical benefit. 13-CRA RDT/rhTSH RIT was
repeated in 8 of 9 scintigraphic responders, and none had
complete or partial response and 44% had progression
within the subsequent 12 months.
Our findings regarding frequency and magnitude of
tumor response are far less favorable than those seen in
the pooled German data [22], in which tumor size
decreased in 6 (12%) evaluable patients, did not change
in 22 (44%), and increased in 9 (18%). However, in that
study 131-I therapy was performed under endogenous
TSH stimulation and patients with decreasing, insufficient
but still present radioiodine as well as complete absence
of radioiodine uptake were included into the study. This
could result in better prognosis for this group of patients.
Data of Courbon et al. [21], where no partial responses
were observed and 45% suffered from disease progres-
sion, more closely resemble our negative findings. We
speculate that two factors could account for the poor clin-
ical outcome of our scintigraphic responders. Firstly, re-
differentiation effect may have been insufficient to obtain
adequate 131-I retention in metastatic tumor cells. Sec-
ondly, the particularly advanced and aggressive tumors,
seen in patients included in our study, may be more radio-
Table 4: Median biochemical response to their first course of 13-cis-retinoic acid
Analyte 
(n: number of evaluated patients)
Median P, Day 42 vs. Day 1 Serum 
Concentrations
Pre-treatment (Day 1) Day 42 Absolute (Relative) Difference,
Day 42 vs. Day 1
Total cholesterol, mg/dL (n = 46) 208 220 20.5 (9.6%) <0,05
Triglycerides, mg/dL (n = 41) 114 171 75.8 (54.1%) <0,05
Aspartate aminotransferase, U/L 
(n = 42)
20 25 3.1 (13.4%) <0,05
Alanine aminotransferase, U/L 
(n = 43)
18 23 2.7 (12.0%) <0,05Thyroid Research 2009, 2:8 http://www.thyroidresearchjournal.com/content/2/1/8
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resistant than most differentiated thyroid carcinomas. It
must be kept in mind that induction of 131-I uptake by a
tumor cell is only a first step in successful radioiodine
treatment: the cell must be exposed to the radiation for a
sufficient length of time, and must be susceptible to the
cytotoxic effect of radiation.
Of note, our study differs from the other 13-CRA RDT tri-
als discussed above in two respects. Firstly, radioiodine
therapy was applied not after THW but after rhTSH stim-
ulation. Secondly, our study included no patient with
weak or equivocal pre-RDT metastatic uptake; in all cases,
the most recent pre-RDT rxWBS was completely negative
for metastatic uptake (albeit 10 of our 53 patients had
some faint thyroid bed uptake on those scans). We are
aware of single reports indicating on the better radioiod-
ine uptake after THW than after rhTSH [26,27]. However,
in the vast majority of cases of rhTSH-aided treatment of
advanced differentiated thyroid cancer reported to date,
the 131I uptake has been adequate [28,29]. Our own
experience with rhTSH aided 131-I treatment of func-
tional thyroid cancer metastases is good [29]. Only 1
(3%) of 31 patients with functional metastases lost radio-
iodine uptake during rhTSH-aided treatment (31), a loss
that was rather related to disease progression than to the
stimulation method. Therefore, in our opinion, the results
of the present study argue that at least in patients with
absent rather than greatly diminished function pre-RDT,
13-CRA does not influence radioiodine uptake in the clin-
ically relevant manner.
A limitation of the present study was that we evaluated 12
months' clinical outcome only in a small fraction of
patients, the 8 of 9 scintigraphic responders who received
subsequent study treatments. For ethical and practical rea-
sons, we did not ask scintigraphic non-responders, (many
of whom were in poor general condition, lived relatively
far from our tertiary referral center, or both) to return for
follow-up. Given the paucity of published clinical data on
direct cytotoxic effects of RAs on NMTC, we believe it
unlikely that patients experienced clinical benefit of 13-
CRA RDT in the absence of scintigraphic response.
Study regimen with 13-CRA was relatively non-toxic: side
effects resolved within 2 weeks of 13-CRA discontinuation
and were generally mild. All patients completed therapy
and 48 of 53, or 91%, tolerated escalation in the second
week of therapy from the starting dose of 1 mg/kg of body
weight/day to 1.5 mg/kg/day. However, side effects were
nearly universal: 52 of 53, or 98% of patients had at least
one symptom. Mean serum total cholesterol and ami-
notransferase levels rose significantly despite the absence
of THW and hence, hypothyroidism. Nevertheless, this
was of no clinical importance as in none of the patients
during study or follow-up symptomatic stroke, heart
attack, vein thrombosis or liver disease developed. Simon
et al [19] reported side effects in 50% of patients treated
with 13-CRA, mainly, skin reaction like in our study.
There was also an increase in triglycerides concentration
in their study, however, statistically not significant (data
extracted from the raw data in the original manuscript).
Conclusion
Our and other studies suggest that, especially in patients
with non functional NMTC metastases, 13-CRA induces
uptake in only a small minority of patients and produces
clinical benefit in few if any of those individuals. Further
investigation of RDT should focus on new RA derivatives
and new adjuvant re-differentiating and radio-sensitizing
strategies. Additionally, better predictive factors should be
identified for scintigraphic and clinical response. In that
regard, in vitro work [10,14,30] suggests that thyroid can-
cer re-differentiation with RA requires both intact RA
receptor (RAR) expression and pathways in target cells: to
respond to retinoid therapy with suppressed proliferation
and increased apoptosis, a cell must express the RAR iso-
forms, RARβ and RXRγ. Bexarotene, a retinoid × receptor
activator, raised some new hopes of effective redifferenti-
ation therapy of NMTC but clinical experiences were
rather disappointing as there was a poor matching
between radioiodine uptake and metastatic foci visible in
computer tomography [31]. Finally, targeted therapeutic
strategies other than RA RDT, e.g., kinase inhibitors, merit
considerable attention [32,33].
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